HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study

Antiviral Therapy

Volumn 8, Issue 2, 2003, Pages 111-120

  Ait Khaled, Mounir ^a   Rakik, Abdelrahim ^a   Griffin, Philip ^a   Stone, Chris ^a   Richards, Naomi ^a   Thomas, Deborah ^b   Falloon, Judith ^c   Tisdale, Margaret ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; THYMIDINE DERIVATIVE;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUTATIONAL ANALYSIS; NONHUMAN; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TREATMENT OUTCOME; VIROLOGY; VIRUS GENE; VIRUS ISOLATION;

EID: 0038369071     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.1177/135965350300800205     Document Type: Article

References (21)

1. Daluge SM, Good SS, Faletto MB, Miller WH, St Clair MH, Boone LR, Tisdale M, Parry N, Reardon JE, Dornsife RE, Averett DA & Krenitsky TA. 1592US9, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrobial Agents & Chemotherapy 1997; 41:1082-1093.
2. Tisdale M, Alnadaf T & Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrobial Agents & Chemotherapy 1997; 41:1094-1098.
3. Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Schlomo Stazewski S, Katlama C, Pearce G & Tisdale M. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and after addition of zidovudine and lamivudine. AIDS 2000; 14(2):163-171.
4. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W & the CNAAB3005 International Study Team. Abacavir-lamivudine zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults. Journal of the American Medical Association 2001; 285(9):1155-1163.
5. Lanier ER, Hellmann N, Scott J, Ait-Khaled M, Melby T, Paxinos E, Werhane H, Petropoulos C, Kusaba E, St Clair M, Smiley L & Lafon S. Determination of a clinically relevant 'cutoff' for abacavir using the Phenosense assay. Abstracts of the 8th Conference on Retroviruses & Opportunistic Infections, Chicago, Ill., USA. Abstract/Poster Number 254.
6. Ait-Khaled M, Rakik A, Griffin P, Gould J, Cutrel A, Fischl M & the CNA3003 International Study Group. Viral rebound during 48 wks of ABC/3TC/ZDV combination therapv in antiretroviral naive adults is infrequent with emergent virus showing a limited number of resistance mutations. Antiviral Therapy 1999; 4(Suppl. 1):52.
7. Melby T, Tortell S, Thorborn D, Pearce G, Spreen W, Scott J, Madison S, Lafon S & Lanier ER. Time to appearance of NRTI-associated mutations and response to subsequent therapy for patients on failing ABC/COM. Abstracts of the 8th Conference on Retroviruses & Opportunistic Infections, Chicago, Ill., USA. Abstract/Poster Number 448.
8. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ & Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New England Journal of Medicine 1999; 341:1865.
9. Schinazi RF, Larder BA & Mellors JW. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. International Antiviral News 2000; 8(5).
10. Kleim JP, Rosner M, Winkler I, Paessens A, Kirsch R, Hhsiou Y, Arnold E & Riess G. Selective pressure of a quinoxaline non-nucleoside inhibitor of human immunodeficiencv virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74 to Val or Ile and Val-75 to leu or Ile) HIV-1 mutants. Proceedings of the National Academy of Sciences, USA 1996; 93:34-38.
11. Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, Bolling L, Aujay M, Wang X, Ellis D, Becker MF, Lasut AL, George HJ, Spadling DR, Hollis G & Abremski K. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrobial Agents & Chemotherapy 2000; 44(9):2475-2484.
12. 3: AIDS Clinical Trials Group Protocol 208. Journal of Infectious Diseases 1995; 172:1379-1383.
13. Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, Huraux JM, Katlama C & Calvez V. Resistance profile and cross-resistance of HIV-1 among patients filing a non-nucleoside reverse transcriptase inhibitor-containing regimen. Journal of Medical Virology 2001; 65(3):445-448.
14. Miller V, de Bethume RP, Korber A, Sturmer M, Hertogs K, Pauwels R, Stoffels P & Staszewski S. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrobial Agents & Chemotherapy 1998; 42(12):3123-3129.
15. Falloon J, Ait-Khaled M, Thomas D, Brosgart C, Eron J.J, Feinberg J, Flanigan T, Hammer S, Kraus PW, Murphy R, Torres R, Masur H & the CNA2007 Study Team. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS 2002; 16:387-396.
16. Tisdale M, Myers R, Randall S, Maguire M, Ait-Khaled M, Elston R & Snowden W. Resistance to the HIV protease inhibitor amprenavir in vitro and in clinical studies - a review. Clinical Drug Investigation 2000; 20(4):267-285.
17. Maguire MF, Shortino D, Klein A, Harris W, Manohitharajah V, Tisdale M, Elston R, Yeo J, Randall S, Xu F, Parker H, May J & Snowden W. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrobial Agents Chemotherapy 2002; 46(3):731-738.
18. Elston R, Randall S, Xu F, Harris W, Manohitharajah V, Maguire M, Rakik A, Ait-Khaled M, Stein D, Tisdale M & Snowden W. High plasma trough levels favour the selection of the I50V mutation pathway during development of APV resistance. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, 2-4 April, 2001, Noordwijk, The Netherlands. Poster 5.1
19. Maguire MF, Guinea R, Griffin P, Macmanus S, Elston RC, Wolfram J, Richards N, Hanlon M, Porter D, Wrin T, Parkin N, Tisdale M, Furfine E, Petropoulos C, Snowden WB & Kleim JP. Human immunodeficiency virus type 1 p1/p6 protease cleavage site changes at gag positions L449 or P453 are linked to I50V protease mutants. Journal of Virology 2002; 76(15):7398-7406.
20. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M & Henfrey RD. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993; 365(6447):671-673.
21. Fang G, Zhu G, Burger H, Keithly JS & Weiser B. Minimising DNA recombination during long RT-PCR. Journal of Virological Methods 1998; 76(1-2):139-148.